Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
NewsHome
Welcome to the Boehringer Ingelheim NewsHome ...

Welcome to the Boehringer Ingelheim NewsHome

This website is your one-stop destination for media information from Boehringer Ingelheim. Quickly find engaging and visualised materials like infographics, videos and animations across a range of different therapeutic areas. Intelligent filtering options make finding the content you're looking for easy and all materials are available for individual or bulk download for your convenience.

 
BI @ ASCO 2013
Lung Cancer: Not Just One Disease
New Phase III data for afatinib* and nintedanib...
Social Sharing Thumbnail

BI @ ASCO 2013
Lung Cancer: Not Just One Disease

New Phase III data for afatinib* and nintedanib* to be presented at the ASCO 2013 Annual Meeting (American Society of Clinical Oncology)

Read more >
 
Treatment evolution infographic
About the evolution of HCV treatment
Treatment evol 2

Treatment evolution infographic

About the evolution of HCV treatment

Read more >
 
Liver damage
Progression of liver damage
Liver damage 2

Liver damage

Progression of liver damage

Read more >
 
HCV infographic
About hepatitis C (HCV)
Hep C 2

HCV infographic

About hepatitis C (HCV)

Read more >
 
About hepatitis C (HCV)
Backgrounder about HCV
HCV backgrounder 2

About hepatitis C (HCV)

Backgrounder about HCV

Read more >
 
HCV risk factors infographic
About HCV risk factors and treatment
Risk factors 2

HCV risk factors infographic

About HCV risk factors and treatment

Read more >
 
EASL 2013
STARTVerso™1 Phase III results
EASL 2013 image2

EASL 2013

STARTVerso™1 Phase III results

Read more >
 
Company logo
Boehringer Ingelheim logo
BI logo 2

Company logo

Boehringer Ingelheim logo

Read more >
 
HCV
The hepatitis C virus
HCV_virus 2

HCV

The hepatitis C virus

Read more >
 
Used syringes
A HCV risk factor
Used syringes 2

Used syringes

A HCV risk factor

Read more >
 
IV drug use
A HCV risk factor
IV drug use 2

IV drug use

A HCV risk factor

Read more >
 
Blood transfusion
A HCV risk factor
Blood 2

Blood transfusion

A HCV risk factor

Read more >
 
Tattoos
A HCV risk factor
Tatoo 2

Tattoos

A HCV risk factor

Read more >
 
Body piercing
A HCV risk factor
Body piercing 2

Body piercing

A HCV risk factor

Read more >
 
Faldaprevir* MOA
Mode of action of faldaprevir
Faldaprevir* MOA 2

Faldaprevir* MOA

Mode of action of faldaprevir

Read more >
 
Faldaprevir* target
Inhibition target
Faldaprevir* target 2

Faldaprevir* target

Inhibition target

Read more >
 
BI 207127* MOA
Mode of action of BI 207127
BI 207127* MOA 2

BI 207127* MOA

Mode of action of BI 207127

Read more >
 
BI 207127 target
HCV polymerase inhibition
BI 207127* target 2

BI 207127 target

HCV polymerase inhibition

Read more >
 
The Economic Burden of VTE
This infographic shows the economic burden of v...
The economic burden of VTE_460X290

The Economic Burden of VTE

This infographic shows the economic burden of venous thromboembolism (VTE)

Read more >
 
What is DVT?
This infographic explains deep vein thrombosis ...
What is DVT_460x290

What is DVT?

This infographic explains deep vein thrombosis (DVT)

Read more >
 
What is PE?
This infographic explains pulmonary embolism (PE)
What is PE_460x290

What is PE?

This infographic explains pulmonary embolism (PE)

Read more >
 
FDA perspective on Pradaxa® published in NEJM
For Non-US, Non-UK & Non-Canadian Media Only ...
Asset Detail 3

FDA perspective on Pradaxa® published in NEJM

For Non-US, Non-UK & Non-Canadian Media Only Released on 26.03.2013

Read more >
 
Physician education collaboration announced at ACC
For Non-US, Non-UK & Non-Canadian Media Only ...
China CME 460 x 290

Physician education collaboration announced at ACC

For Non-US, Non-UK & Non-Canadian Media Only Released on 11.03.2013

Read more >
 
STARTVerso4 data in HCV/HIV co-infected patients
Interim Phase III results in HIV patients co-in...
CROI2013_2

STARTVerso4 data in HCV/HIV co-infected patients

Interim Phase III results in HIV patients co-infected with hepatitis C

Read more >
 
AAAAI - Tiotropium Respimat® press release
Tiotropium* Respimat® is effective in symptomat...
AAAAI_pressrel_thumb2

AAAAI - Tiotropium Respimat® press release

Tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status

Read more >
 
Results from the RE-MEDY and RE-SONATE trials
FOR NON-US/UK/CANADIAN AUDIENCES ONLY
RE-MEDY RE-SONATE Press Release

Results from the RE-MEDY and RE-SONATE trials

FOR NON-US/UK/CANADIAN AUDIENCES ONLY

Read more >
 
Olodaterol PADAC press release
Press release announcing a positive recommendat...
olo_press-release_Thumbnail

Olodaterol PADAC press release

Press release announcing a positive recommendation for olodaterol

Read more >
 
Olodaterol backgrounder
Background information on olodaterol
olo_media_backgrounder_Thumbnail

Olodaterol backgrounder

Background information on olodaterol

Read more >
 
HCVerso interferon-free Hepatitis C trial for Faldaprevir*
First patients enrolled into Phase III interfer...
PhIII FPI SOUNDC3 2

HCVerso interferon-free Hepatitis C trial for Faldaprevir*

First patients enrolled into Phase III interferon-free trial & SOUND-C3 results

Read more >
 
Phase III interferon-free trials
Details of the Phase III trial discussed
HCV_Prof_Sarrazin

Phase III interferon-free trials

Details of the Phase III trial discussed

Read more >
 
Glossary of Terms
A glossary of terms relating to AF, DVT and PE
AF Glossary 460x290

Glossary of Terms

A glossary of terms relating to AF, DVT and PE

Read more >
 
Patient Outcomes After A Major Bleed
FOR NON-US/UK/CANADIAN AUDIENCES ONLY Release...
Thumbnail_ASH_Press_Release

Patient Outcomes After A Major Bleed

FOR NON-US/UK/CANADIAN AUDIENCES ONLY Released on 10.12.2012

Read more >
 
Curtain Raiser - New data to be presented at ASH 2012
FOR NON-US/UK AUDIENCES ONLY Released on 05.12....
Ash Thumbnail

Curtain Raiser - New data to be presented at ASH 2012

FOR NON-US/UK AUDIENCES ONLY Released on 05.12.2012

Read more >
 
About faldaprevir*
Backgrounder about faldaprevir
Faldaprevir backgrounder 2

About faldaprevir*

Backgrounder about faldaprevir

Read more >
 
About BI 207127*
Backgrounder about BI 207127
BI 207127 backgrounder 2

About BI 207127*

Backgrounder about BI 207127

Read more >
 
About HCV clinical trials
Backgrounder about BI’s clinical trials
Clinical trials backgrounder 2

About HCV clinical trials

Backgrounder about BI’s clinical trials

Read more >
 
Boehringer Ingelheim in hepatitis C
Backgrounder about Boehringer Ingelheim in HCV
HCV portfolio backgrounder 2

Boehringer Ingelheim in hepatitis C

Backgrounder about Boehringer Ingelheim in HCV

Read more >
 
AASLD 2012
SOUND-C2 final results
AASLD Press Release Thumbnail

AASLD 2012

SOUND-C2 final results

Read more >
 
AASLD 2012
New data from our investigational HCV portfolio...
AASLD home 3

AASLD 2012

New data from our investigational HCV portfolio will be presented at The Liver MeetingTM 2012 in Boston

Read more >
 
Dabigatran Etexilate (Pradaxa®)
Providing further info on the novel oral antico...
Thumb Dabigatran backgrounder

Dabigatran Etexilate (Pradaxa®)

Providing further info on the novel oral anticoagulant, Pradaxa®

Read more >
 
Results from RE-LY® and RELY-ABLE®
Safe and effective long-term stroke prevention ...
thumbnail RELY RELYABLE Backgrounder

Results from RE-LY® and RELY-ABLE®

Safe and effective long-term stroke prevention with Pradaxa®: Results from RE-LY® and RELY-ABLE®

Read more >
 
Press Release - AHA 2012 New RELY-ABLE® Data Presented
FOR NON-US/UK AUDIENCES ONLY Released on 08.11...
thumbnail RELYABLE Press Release

Press Release - AHA 2012 New RELY-ABLE® Data Presented

FOR NON-US/UK AUDIENCES ONLY Released on 08.11.2012

Read more >
 
Importance of Long-Term Data
FOR NON-US/UK AUDIENCES ONLY Supplement on imp...
thumbnail AF Factsheet

Importance of Long-Term Data

FOR NON-US/UK AUDIENCES ONLY Supplement on importance of long-term clinical data

Read more >
 
Atrial Fibrillation and Stroke
Background Information
thumbnail AF and Stroke Backgrounder

Atrial Fibrillation and Stroke

Background Information

Read more >
 
Press Release - New real-world data on VTE prevention
FOR NON-US/UK AUDIENCES ONLY Released on 06.11...
thumbnail VTE real World

Press Release - New real-world data on VTE prevention

FOR NON-US/UK AUDIENCES ONLY Released on 06.11.2012

Read more >
 
Press Release – Ongoing Development of Antidote for Dabigatran
FOR NON-US/UK AUDIENCES ONLY Released on 05.11...
thumbnail Antidote development press release

Press Release – Ongoing Development of Antidote for Dabigatran

FOR NON-US/UK AUDIENCES ONLY Released on 05.11.2012

Read more >
 
RELY-ABLE®:The reality of long-term use of PRADAXA® IN AF
FOR NON-US/UK AUDIENCES ONLY Announcing the l...
AHA media invite 2by1

RELY-ABLE®:The reality of long-term use of PRADAXA® IN AF

FOR NON-US/UK AUDIENCES ONLY Announcing the long-term RELY-ABLE® clinical trial data for Pradaxa®, presented at the AHA Scientific Sessions, 2012.

Read more >
 
About hepatitis C (5)
How is hepatitis C diagnosed?
Diagnosis

About hepatitis C (5)

How is hepatitis C diagnosed?

Read more >
 
Treatment of hepatitis C (1)
Hepatitis C is curable
Curable

Treatment of hepatitis C (1)

Hepatitis C is curable

Read more >
 
About hepatitis C (6)
What are hepatitis C genotypes?
genotypes

About hepatitis C (6)

What are hepatitis C genotypes?

Read more >
 
Treatment of hepatitis C (3)
Limitations of hepatitis C treatments
Limitations

Treatment of hepatitis C (3)

Limitations of hepatitis C treatments

Read more >
 
About hepatitis C (3)
What are the long-term complications of hepatit...
Complications

About hepatitis C (3)

What are the long-term complications of hepatitis C?

Read more >
 
Treatment of hepatitis C (4)
The future of hepatitis C treatment
future

Treatment of hepatitis C (4)

The future of hepatitis C treatment

Read more >
 
About hepatitis C (1)
What is hepatitis C and how do you get it?
What

About hepatitis C (1)

What is hepatitis C and how do you get it?

Read more >
 
About hepatitis C (4)
Who is affected by hepatitis C?
Who2

About hepatitis C (4)

Who is affected by hepatitis C?

Read more >
 
Treatment of hepatitis C (2)
Hepatitis C treatment approaches
approaches

Treatment of hepatitis C (2)

Hepatitis C treatment approaches

Read more >
 
Impact of hepatitis C (3)
The economic impact of hepatitis C
econcomic

Impact of hepatitis C (3)

The economic impact of hepatitis C

Read more >
 
Impact of hepatitis C (1)
The emotional impact of hepatitis C
emotional

Impact of hepatitis C (1)

The emotional impact of hepatitis C

Read more >
 
Impact of hepatitis C (2)
Stigma associated with hepatitis C
stigma

Impact of hepatitis C (2)

Stigma associated with hepatitis C

Read more >
 
About hepatitis C (2)
What are the symptoms of hepatitis C?
symptoms

About hepatitis C (2)

What are the symptoms of hepatitis C?

Read more >
 
Faldaprevir* infographic
About faldaprevir
Faldaprevir 2

Faldaprevir* infographic

About faldaprevir

Read more >
 
DAA infographic
About direct-acting antivirals
DAA 2

DAA infographic

About direct-acting antivirals

Read more >
 
Risk of Stroke for People with AF
This infographic demonstrates the risk of strok...
thumbnail Risk of Stroke for People with Atrial Fibrillation

Risk of Stroke for People with AF

This infographic demonstrates the risk of stroke for people with atrial fibrillation (AF)

Read more >
 
Curtain Raiser - Clinical Data Presentations at AHA 2012
FOR NON-US/UK AUDIENCES ONLY Released on 31.10...
thumbnail curtain raiser

Curtain Raiser - Clinical Data Presentations at AHA 2012

FOR NON-US/UK AUDIENCES ONLY Released on 31.10.2012

Read more >
 
Respiratory R&D
Press release about respiratory Research & Deve...
R&D day press release_preview

Respiratory R&D

Press release about respiratory Research & Development

Read more >
 
Respiratory timeline
Boehringer Ingelheim heritage
R&D timeline_preview

Respiratory timeline

Boehringer Ingelheim heritage

Read more >
 
R&D show reel
Press conference highlights
R&D_video_thumbnail

R&D show reel

Press conference highlights

Read more >
 
Respiratory R&D media day
Respiratory Research & Development press confer...
RD day event_2

Respiratory R&D media day

Respiratory Research & Development press conference

Read more >
 
GLORIATM -AF Registry Program
This backgrounder provides information on GLORI...
thumbnail GLORIA

GLORIATM -AF Registry Program

This backgrounder provides information on GLORIATM -AF registry

Read more >
 
Ischaemic Stroke in Atrial Fibrillation
This backgrounder is about the link between AF ...
thumbnail ISCHAEMIC STROKE IN ATRIAL FIBRILLATION

Ischaemic Stroke in Atrial Fibrillation

This backgrounder is about the link between AF and ischaemic stroke

Read more >
 
Speak About AF Survey
This backgrounder is about the largest and most...
thumbnail SPEAK ABOUT AF SURVEY

Speak About AF Survey

This backgrounder is about the largest and most extensive survey ever conducted in patients diagnosed with AF and physicians who treat the condition

Read more >
 
IPF press release
Recruitment complete for two pivotal Phase III ...
Recruitment complete_thumbnail

IPF press release

Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis

Read more >
 
Boehringer Ingelheim submits first compound
BI submits first oncology compound, afatinib* f...
Boehringer_Ingelheim_submits_first_thumb

Boehringer Ingelheim submits first compound

BI submits first oncology compound, afatinib* for European approval

Read more >
 
Graphic of information about COPD
Facts and statistics about COPD
2012 08 17_COPD infographic FINAL.JPG

Graphic of information about COPD

Facts and statistics about COPD

Read more >
 
COPD media backgrounder
Background information for media about COPD
COPD Media Backgrounder FINAL.JPG

COPD media backgrounder

Background information for media about COPD

Read more >
 
Asthma media backgrounder
Backgrounder for media about asthma
Asthma Media Backgrounder ERS 2012 FINAL.JPG

Asthma media backgrounder

Backgrounder for media about asthma

Read more >
 
Clinical Trials E-Booklet Chapter 1
Introduction & Design of a Clinical Trial
eBooklet1-thumb

Clinical Trials E-Booklet Chapter 1

Introduction & Design of a Clinical Trial

Read more >
 
Clinical Trials E-Booklet Chapter 2
Elements of a Clinical Trial
eBooklet2-thumb

Clinical Trials E-Booklet Chapter 2

Elements of a Clinical Trial

Read more >
 
Clinical Trials E-Booklet Chapter 3
Clinical Trial Endpoints
eBooklet3-thumb

Clinical Trials E-Booklet Chapter 3

Clinical Trial Endpoints

Read more >
 
Clinical Trials E-Booklet Chapter 5
Clinical Trial Statistics
eBooklet5-thumb

Clinical Trials E-Booklet Chapter 5

Clinical Trial Statistics

Read more >
 
Clinical Trials E-Booklet Chapter 6
Summary, Checklist & Glossary
eBooklet6-thumb

Clinical Trials E-Booklet Chapter 6

Summary, Checklist & Glossary

Read more >
 
Atrial Fibrillation and Stroke
This infographic shows how atrial fibrillation ...
Thumbnail Atrial Fibrillation and Stroke

Atrial Fibrillation and Stroke

This infographic shows how atrial fibrillation leads to stroke

Read more >
 
Drug Interaction Associated with VKAs
This infographic shows the common drug interact...
thumbnail Drug Interactions with Vitamin K Antagonists (VKAs)

Drug Interaction Associated with VKAs

This infographic shows the common drug interaction associated with Vitamin K Antagonists (VKAs)

Read more >
 
LUX-Lung 3 Results - Prof James Yang
Interview with Prof James-Chih-Hsin Yang Direc...
LUX_Lung_3_Results_Prof_James_Yang_2by1

LUX-Lung 3 Results - Prof James Yang

Interview with Prof James-Chih-Hsin Yang Director of the Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan

Read more >
 
Pivotal study on afatinib
Pivotal study on afatinib may challenge standar...
Pivotal_study_on_afatinib_thumb

Pivotal study on afatinib

Pivotal study on afatinib may challenge standard first line treatment

Read more >
 
Importance of EGFR Mutation Testing
Interview with Dr Vera Hirsh Associate Profess...
Importance_of_EGFR_Mutation_Testing_2by1

Importance of EGFR Mutation Testing

Interview with Dr Vera Hirsh Associate Professor, McGill University Department of Medical Oncology Royal Victoria Hospital, Montreal, Canada

Read more >
 
LUX-Lung 3 Results - Prof Thomas Lynch
Interview with Prof Thomas J. Lynch, MD Direct...
LUX_Lung_3_Results_Prof_Thomas_Lynch_2by1

LUX-Lung 3 Results - Prof Thomas Lynch

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Read more >
 
LUX-Lung 3 Trial Design
Interview with Prof Tony Shu Kam Mok, MD Depar...
LUX_Lung_3_Trial_Design_Prof_Tony_Mok_2by1

LUX-Lung 3 Trial Design

Interview with Prof Tony Shu Kam Mok, MD Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong

Read more >
 
LUX-Lung 6 and other Afatinib Trials
Interview with Prof James-Chih-Hsin Yang Direc...
LUX_Lung_6_Dr_James_Yang_2by1

LUX-Lung 6 and other Afatinib Trials

Interview with Prof James-Chih-Hsin Yang Director of the Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan

Read more >
 
LUX-Lung 7 & 8 Trials
Interview with Prof Thomas J. Lynch, MD Direct...
LUX_Lung_7_8_Trials_Prof_Thomas_Lynch_2by1

LUX-Lung 7 & 8 Trials

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Read more >
 
“Hepatitis Academy” (1)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (1)

Educational webcast on HCV

Read more >
 
"Hepatitis Academy" (2)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

"Hepatitis Academy" (2)

Educational webcast on HCV

Read more >
 
“Hepatitis Academy” (3)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (3)

Educational webcast on HCV

Read more >
 
“Hepatitis Academy” (4)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (4)

Educational webcast on HCV

Read more >
 
“Hepatitis Academy” (5)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (5)

Educational webcast on HCV

Read more >
 
“Hepatitis Academy” (6)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (6)

Educational webcast on HCV

Read more >
 
“Hepatitis Academy” (7)
Educational webcast on HCV
2x1_Thumbnail_Hep_Acad

“Hepatitis Academy” (7)

Educational webcast on HCV

Read more >
 
Pivotal Phase III Results
Media Alert: Pivotal Phase III Results for Afat...
Pivotal_Phase_III_Results_thumb

Pivotal Phase III Results

Media Alert: Pivotal Phase III Results for Afatinib to be Presented at ASCO 2012

Read more >
 
Gregory Lip: What is the GLORIATM AF Registry?
In this video, Prof. Gregory Lip introduces the...
try_2by1

Gregory Lip: What is the GLORIATM AF Registry?

In this video, Prof. Gregory Lip introduces the GLORIATM AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.

Read more >
 
Gregory Lip: The Importance of Running a Truly Global Patient Registry
In this video, Professor Gregory Lip talks abou...
try2_2by1

Gregory Lip: The Importance of Running a Truly Global Patient Registry

In this video, Professor Gregory Lip talks about GLORIATM – AF registry program and explains how important it is to run a truly patient registry

Read more >
 
Gregory Lip: The Importance of the GLORIATM -AF Registry in Light of the Introduction of Multiple NOACs
In this video, Professor Gregory Lip talks abou...
try3_2by1

Gregory Lip: The Importance of the GLORIATM -AF Registry in Light of the Introduction of Multiple NOACs

In this video, Professor Gregory Lip talks about the GLORIATM - AF registry program and its importance in light of the introduction of multiple novel oral anticoagulants

Read more >
 
Gregory Lip: Why Obtaining Real-World Data is So Important
In this video, Professor Gregory Lip talks abou...
try4_2by1

Gregory Lip: Why Obtaining Real-World Data is So Important

In this video, Professor Gregory Lip talks about the GLORIATM -AF registry program and why obtaining real-world data is so important

Read more >
 
EASL 2012
SOUND-C2 interim results
EASL 2012 SOUND-C 3

EASL 2012

SOUND-C2 interim results

Read more >
 
EASL 2012
SOUND-C2 interim liver cirrhosis data
EASL 2012 cirrhotic 2

EASL 2012

SOUND-C2 interim liver cirrhosis data

Read more >
 
Low Incidence of ICH
Released on 18.04.2012
Dabigatran etexilate thumb

Low Incidence of ICH

Released on 18.04.2012

Read more >
 
Hepatitis C glossary
Explaining HCV terms
Glossary 2

Hepatitis C glossary

Explaining HCV terms

Read more >
 
"Data to Design"
About HCV trials
Data to design 2

"Data to Design"

About HCV trials

Read more >
 
LUX-Head & Neck 1 & 2 Trial Initiation
BI moves into Phase III for its Head and Neck C...
LUX-Head & Neck Trial Initiation thumb

LUX-Head & Neck 1 & 2 Trial Initiation

BI moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

Read more >
 
Afatinib
Interview with Prof Thomas J. Lynch, MD Direct...
Afatinib_Prof_Thomas_Lynch_2by1

Afatinib

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Read more >
 
Biomarkers
Interview with Prof Thomas J. Lynch, MD Direct...
Biomarkers_Prof_Thomas_Lynch_2by1

Biomarkers

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Read more >
 
State of Research in Ovarian Cancer
Interview with Jonathan Ledermann, BSc, MD, FRC...
State_of_Research_in_Ovarian_Cancer_2by1

State of Research in Ovarian Cancer

Interview with Jonathan Ledermann, BSc, MD, FRCP Cancer Research UK and UCL Cancer Institute London, UK

Read more >
 
AASLD 2011
SILEN-C1 and SILEN-C3 data
AASLD 2011 SILEN-C 2

AASLD 2011

SILEN-C1 and SILEN-C3 data

Read more >
 
AASLD 2011
SOUND-C2 interim data
AASLD 2011 SOUND-C 2

AASLD 2011

SOUND-C2 interim data

Read more >
 
Characteristics and Symptoms of Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...
Characteristics_and_Symptoms_of_Ovarian_Cancer_2by1

Characteristics and Symptoms of Ovarian Cancer

Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia

Read more >
 
Ovarian Cancer Prognosis
Interview with Professor Ignace Vergote Chairm...
Ovarian_Cancer_Prognosis_2by1

Ovarian Cancer Prognosis

Interview with Professor Ignace Vergote Chairman of the Leuven Cancer Institute

Read more >
 
Targeted Therapies in Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...
Targeted_Therapies_in_Ovarian_Cancer_2by1

Targeted Therapies in Ovarian Cancer

Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia

Read more >
 
Head and Neck Cancer
Interview with Ezra Cohen, MD Associate Profes...
Head_and_Neck_Cancer_Ezra_Cohen_2by1

Head and Neck Cancer

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Read more >
 
Head and Neck Cancer Treatments
Interview with Ezra Cohen, MD Associate Profes...
Head_and_Neck_Cancer_Treatments_Ezra_Cohen_2by1

Head and Neck Cancer Treatments

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Read more >
 
Head and Neck Cancer Trials
Interview with Ezra Cohen, MD Associate Profes...
Head_and_Neck_Cancer_Trials_Ezra_Cohen_2by1

Head and Neck Cancer Trials

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Read more >
 
BIBF 1120* in mCRC
BIBF 1120* in patients with metastatic colorect...
Press Release BIBF 1120 in mCRC thumb

BIBF 1120* in mCRC

BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events

Read more >
 
Lux Breast Cancer Trial August 2011
Boehringer Ingelheim Broadens its Breast Cancer...
Pressrelease LUX-Breast cancer trial 2011 thumb

Lux Breast Cancer Trial August 2011

Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*

Read more >
 
Consumer Media Factsheet about AF
This factsheet provides information on atrial f...
thumbnail Consumer FS

Consumer Media Factsheet about AF

This factsheet provides information on atrial fibrillation (AF)

Read more >
 
A-Z Cancer Glossary
The terminology around cancer research and canc...
A-Z Cancer Glossary thumb

A-Z Cancer Glossary

The terminology around cancer research and cancer treatments

Read more >
 
EASL 2011
Faldaprevir Phase III trial design
EASL 2011 PIII 2

EASL 2011

Faldaprevir Phase III trial design

Read more >
 
EASL 2011
SILEN-C1 and SILEN-C2 data
EASL 2011 SILEN-C 2

EASL 2011

SILEN-C1 and SILEN-C2 data

Read more >
 
New Lux-Lung 1 data December 2010
New subgroup analysis of the LUX-Lung 1 trial s...
New Lux-Lung 1 data December 2010 thumb

New Lux-Lung 1 data December 2010

New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients likely to have EGFR mutations

Read more >
 
Angiokinase inhibitors in lung cancer
Interview with Marianne Nicolson, MD, FRCP Con...
Angiokinase_inhibitors_in_lung_cancer_2by1

Angiokinase inhibitors in lung cancer

Interview with Marianne Nicolson, MD, FRCP Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland

Read more >
 
Personalising cancer care and the future of cancer treatments
Interview with John Heymach, MD, PhD Associate...
Personalising_cancer_care_John_Heymach_2by1

Personalising cancer care and the future of cancer treatments

Interview with John Heymach, MD, PhD Associate Professor, MD Anderson Cancer Center, Houston, Texas, USA

Read more >
 
Could new cancer targets change the outlook for personalised medicine?
Interview with Kathleen Pritchard, MD, FRCPC T...
outlook_for_personalised_medicine_Kathleen_Pritchard_2by1

Could new cancer targets change the outlook for personalised medicine?

Interview with Kathleen Pritchard, MD, FRCPC Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada

Read more >
 
Non small cell lung cancer overview
Interview with David Ross Camidge, MD, PhD As...
Non_small_cell_lung_cancer_David_Camidge_2by1

Non small cell lung cancer overview

Interview with David Ross Camidge, MD, PhD Assistant Professor, University of Colorado, Denver, Colorado, USA

Read more >
 
Afatinib lung cancer trial results
Afatinib (BIBW 2992*) triples progression free ...
Afatinib lung cancer trial results thumb

Afatinib lung cancer trial results

Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients

Read more >
 
LUX-Breast 1 Initiation September 2010
Boehringer Ingelheim Initiates Phase III Clinic...
Press Release LUX-Breast 1 Initiation September 2010 thumb

LUX-Breast 1 Initiation September 2010

Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer

Read more >
 
Atrial Fibrillation Prevalence
This infographic shows the prevalence of atrial...
thumbnail Atrial fibrillation Prevalence and Cost of Treatment in the United States and Europe

Atrial Fibrillation Prevalence

This infographic shows the prevalence of atrial fibrillation (AF) in the United States and Europe

Read more >
 
Increased Hospital Admissions Caused by AF
This infographic demonstrates that the hospital...
thumbnail Increased Hospital Admissions Caused by Atrial Fibrillation

Increased Hospital Admissions Caused by AF

This infographic demonstrates that the hospital admissions caused by atrial fibrillation (AF) rose 60% in the past 20 years

Read more >
 
How Atrial Fibrillation Affects the Heart
This infographic demonstrates how atrial fibril...
thumbnail How Atrial Fibrillation Affects the Heart

How Atrial Fibrillation Affects the Heart

This infographic demonstrates how atrial fibrillation (AF) affects the heart

Read more >
 
Mode of Action of Direct Thrombin Inhibitors
This infographic demonstrates the mode of actio...
thumbnail Mode of Action of Direct Thrombin Inhibitors

Mode of Action of Direct Thrombin Inhibitors

This infographic demonstrates the mode of action of DTIs

Read more >
 
Personal Burden of AF Related Strokes
This infographic shows the personal burden of a...
thumbnail Personal Burden of Atrial Fibrillation Related Strokes

Personal Burden of AF Related Strokes

This infographic shows the personal burden of atrial fibrillation (AF)related strokes

Read more >
 
Risk Factors for Atrial Fibrillation
This infographic lists the common risk factors ...
thumbnail Risk Factors for Atrial Fibrillation

Risk Factors for Atrial Fibrillation

This infographic lists the common risk factors for atrial fibrillation (AF)

Read more >
 
Most Common Causes of VTE
This infographic shows the most common causes o...
Risk Factors AF Small View

Most Common Causes of VTE

This infographic shows the most common causes of venous thromboembolism (VTE)

Read more >
 
Symptoms of VTE
This infographic demonstrates the symptoms of v...
Symptoms of VTE 460x290

Symptoms of VTE

This infographic demonstrates the symptoms of venous thromboembolism (VTE)

Read more >
 
How Common is VTE?
This infographic shows the prevalence of VTE in...
Prevelance VTE

How Common is VTE?

This infographic shows the prevalence of VTE in Europe and the US

Read more >
 
What is VTE?
This infographic shows what VTE is. Deep vein t...
thumbnail What is VTE

What is VTE?

This infographic shows what VTE is. Deep vein thrombosis and pulmonary embolism

Read more >
 
VTE Management
This infographic shows the treatment of acute a...
thumbnail VTE Managment

VTE Management

This infographic shows the treatment of acute and long-term VTE

Read more >
 
BIBW 2992 cancer treatment data
BI's lead investigational oncology compound BIB...
BIBW 2992 cancer treatment data presented at ASCO thumb

BIBW 2992 cancer treatment data

BI's lead investigational oncology compound BIBW 2992* demonstrates...

Read more >
 
Volasertib* (compound code BI 6727)
Volasertib* (compound code BI 6727) is an inves...
Volasertib_compound_code_BI_6727_2by1

Volasertib* (compound code BI 6727)

Volasertib* (compound code BI 6727) is an investigational, potent, and selective inhibitor in vitro of PLK1, an important regulator of the cell cycle.

Read more >
 
LUME-Ovar 1 December 2009
Boehringer Ingelheim initiates first Phase III ...
LUME-Ovar 1 December 2009 thumb

LUME-Ovar 1 December 2009

Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian Cancer

Read more >
 
Boehringer Ingelheim and DxS sign agreement
Boehringer Ingelheim and DxS sign an agreement ...
Boehringer Ingelheim and DxS sign agreement thumb

Boehringer Ingelheim and DxS sign agreement

Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer

Read more >
 
Boehringer Ingelheim to commence Lux Lung 3 study
Boehringer Ingelheim and DxS sign agreement for...
BI to commence Lux Lung 3 study thumb

Boehringer Ingelheim to commence Lux Lung 3 study

Boehringer Ingelheim and DxS sign agreement for a companion diagnostic test to identify EGFR mutations in patients with lung cancer

Read more >
 
Boehringer Ingelheim to present new data at ASCO 2009
Boehringer Ingelheim to Present New Phase II Cl...
Boehringer Ingelheim to present new data thumb

Boehringer Ingelheim to present new data at ASCO 2009

Boehringer Ingelheim to Present New Phase II Clinical Data on two Lead Oncology Compounds at ASCO 2009

Read more >
 
Press release LUME-Lung 1+2 November 2008
First pivotal trials begin for Boehringer Ingel...
LUME-Lung 1+2 November 2008 thumb

Press release LUME-Lung 1+2 November 2008

First pivotal trials begin for Boehringer Ingelheim’s novel triple angiokinase inhibitor BIBF 1120*

Read more >
 
Clinical trials data BIBF 1120*
Data suggests promising overall survival and pr...
Clinical trials data suggests promising thumb

Clinical trials data BIBF 1120*

Data suggests promising overall survival and progression-free survival with BIBF 1120*

Read more >
 
Lux phase 3 BIBW 2992 (afatinib)
New data on BIBW 2992*, a potent, irreversible,...
Lux phase 3 BIBW 2992 thumb

Lux phase 3 BIBW 2992 (afatinib)

New data on BIBW 2992*, a potent, irreversible, second-generation oral signal transduction inhibitor provides glimpse of next chapter in lung cancer care

Read more >
 
BI accesses field of oncology
BI accesses field of oncology with three compou...
Boehringer Ingelheim accesses field of oncology thumb

BI accesses field of oncology

BI accesses field of oncology with three compounds in phase II

Read more >
 
FILTER BY: SHOW ALL  Infographic  Video  Image  Backgrounder  Press release  Fact sheet Other
+ -
< >